Adis Editorial. Mismatched double-stranded RNA polyI:polyC12U. Drugs R D. 2004;5(5):297–304.

Article  Google Scholar 

Abdelwahab A, Palosaari S, Abdelwahab SA, Rifaai RA, El-Tahawy NF, Saber EA, Nousiainen T, Valkealahti M, Huhtakangas J, Karttunen TJ, Lehenkari P. Differential synovial tissue expression of TLRs in seropositive and seronegative rheumatoid arthritis: a preliminary report. Autoimmunity. 2021;54(1):23–34.

Article  CAS  PubMed  Google Scholar 

Abolhassani H, Vosughimotlagh A, Asano T, Landegren N, Boisson B, Delavari S, Bastard P, Aranda-Guillen M, Wang Y, Zuo F, Sardh F, Marcotte H, Du L, Zhang SY, Zhang Q, Rezaei N, Kampe O, Casanova JL, Hammarstrom L, Pan-Hammarstrom Q. X-Linked TLR7 deficiency underlies critical COVID-19 pneumonia in a male patient with ataxia-telangiectasia. J Clin Immunol. 2022;42(1):1–9.

Article  CAS  PubMed  Google Scholar 

Adamus T, Kortylewski M. The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn). 2018;22(1a):56–60.

PubMed  Google Scholar 

Agarwal K, Ahn SH, Elkhashab M, Lau AH, Gaggar A, Bulusu A, Tian X, Cathcart AL, Woo J, Subramanian GM, Andreone P, Kim HJ, Chuang WL, Nguyen MH. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat. 2018;25(11):1331–40.

Article  CAS  PubMed  Google Scholar 

Al-Azab M, Idiiatullina E, Liu Z, Lin M, Hrovat-Schaale K, Xian H, Zhu J, Yang M, Lu B, Zhao Z, Liu Y, Chang J, Li X, Guo C, Liu Y, Wu Q, Chen J, Lan C, Zeng P, Cui J, Gao X, Zhou W, Zhang Y, Zhang Y, Masters SL. Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus. Nat Immunol. 2024;25(6):969–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–8.

Article  CAS  PubMed  Google Scholar 

Alseoudy MM, Elgamal M, Abdelghany DA, Borg AM, El-Mesery A, Elzeiny D, Hammad MO. Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: a case-control study. Clin Immunol. 2022;235: 108929.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alter G, Suscovich TJ, Teigen N, Meier A, Streeck H, Brander C, Altfeld M. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol. 2007;178(12):7658–66.

Article  CAS  PubMed  Google Scholar 

Anderson K, Hsueh CH, Gurtovaya O, Mathur A, Taylor J, Serone A, Othman AA. POS0672 first-in-human study of GS-5718, an oral IRAK-4 inhibitor, in healthy subjects: pharmacokinetics, safety, tolerability, and assessment of effect of food and acid reducing agents on exposure. Ann Rheum Dis. 2021;80(Suppl 1):581.

Article  Google Scholar 

Andon FT, Leon S, Ummarino A, Redin E, Allavena P, Serrano D, Anfray C, Calvo A. Innate and adaptive responses of intratumoral immunotherapy with endosomal toll-like receptor agonists. Biomedicines. 2022;10(7):1590.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.

Article  CAS  PubMed  Google Scholar 

Apostólico JS, Lunardelli VAS, Yamamoto MM, Cunha-Neto E, Boscardin SB, Rosa DS. Poly(I:C) potentiates T cell immunity to a dendritic cell targeted HIV-multiepitope vaccine. Front Immunol. 2019;10:843.

Article  PubMed  PubMed Central  Google Scholar 

Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, Srouji J, Ramesh S, Vyasamneni R, Karki B, Sciuto TE, Sethi H, Dong JZ, Moles MA, Manson K, Rooney MS, Khondker ZS, DeMario M, Gaynor RB, Srinivasan L. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010-1026 e1011.

Article  CAS  PubMed  Google Scholar 

Awad MM, Govindan R, Spigel DR, Garon EB, Kohler V, Vyasamneni R, Ramesh S, Sciuto TE, Moles MA, Tepper J, Wanamaker A, Khondkar ZS, Srouji J, Dong JZ, Balogh KN, Poran A, Bushway ME, DeMario M, Gaynor RB, Srinivasan L. Abstract 73: A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first-line non-squamous NSCLC: Associations with clinical outcomes. Cancer Res. 2021;81(13_Supplement):73–73.

Article  Google Scholar 

Babiker HB, Lenz H-J, Scott AJ, Rahimian S, Overman MJ. Abstract CT265: A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206). Cancer Res. 2020;80(16_Supplement):CT265.

Article  Google Scholar 

Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J, Rissmann R. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clin Immunol. 2017;174:63–72.

Article  CAS  PubMed  Google Scholar 

Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008;223:271–83.

Article  CAS  PubMed  Google Scholar 

Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009;9(8):535–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol. 2006;7(1):49–56.

Article  CAS  PubMed  Google Scholar 

Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98(16):9237–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005;115(11):3265–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Muller-Holzner E, Jones A, Widschwendter M. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 2010;101(4):1059–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berouti M, Lammens K, Heiss M, Hansbauer L, Bauernfried S, Stockl J, Pinci F, Piseddu I, Greulich W, Wang M, Jung C, Frohlich T, Carell T, Hopfner KP, Hornung V. Lysosomal endonuclease RNase T2 and PLD exonucleases cooperatively generate RNA ligands for TLR7 activation. Immunity. 2024;57(7):1482-1496.e1488.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blasius AL, Arnold CN, Georgel P, Rutschmann S, Xia Y, Lin P, Ross C, Li X, Smart NG, Beutler B. Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A. 2010;107(46):19973–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, Rodrigues SD, Calandra T, Francioli P, Telenti A, Speck RF, Aderem A, Swiss HIVCS. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS. 2007;21(4):441–6.

Article  CAS  PubMed  Google Scholar 

Bombardieri M, Kam NW, Brentano F, Choi K, Filer A, Kyburz D, McInnes IB, Gay S, Buckley C, Pitzalis C. A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis. 2011;70(10):1857–65.

Article  CAS  PubMed  Google Scholar 

Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009;625(1–3):41–54.

Article